Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin | PLOS ONE
Commercial Teams
Foundation medicine Comprehensive Genomic Profiling Brochure
Foundation Medicine Liquid Biopsy Gets FDA Okay – ISPE Boston
FoundationOne Liquid CDx
Multi-gene Testing (NGS) for PIK3CA Mutations
Comprehensive genomic profiling in oncology – from vision to reality | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
With its liquid biopsy approval, Foundation Medicine takes on Guardant | Evaluate
fmi-10k_20171231.htm
FDA-approved FoundationOne CDx assays until 22 March 2021. | Download Scientific Diagram
FoundationOne®Liquid CDx
FoundationOne Liquid CDx
FoundationOne Liquid CDx
Compare Our Tests | Foundation Medicine
FoundationOne Liquid CDx (F1 Liquid CDx) – P190032/S005 | FDA
World-leading Genomic Testing Services | Foundation Medicine
Roche FMI landing page
Foundation Medicine Inks $111.5M Genomic Profiling Contract with VA
Our portfolio
FoundationOne Liquid CDx
FoundationOne®Liquid CDx
San Diego Office
FoundationOne Liquid CDx | Foundation Medicine
Foundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings
AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval | Evaluate
FoundationOne Liquid CDx
FoundationOne Liquid CDx
Comprehensive genomic profiling | Foundation Medicine
